Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453814 | 0.79 | GAA (0.50) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL27926914 | 0.79 | LMNA (0.52) | METAP2ALDH1A1CYP3A4HIF1ATSHR | |
| SCHEMBL8342585 | 0.75 | GAA (0.55) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL4760703 | 0.73 | NPC1 (0.45) | NCF1ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL4071976 | 0.72 | NOTUM (0.46) | CYP1A2CYP2C9CYP2C19MAP3K5NOTUM | |
| SCHEMBL8342753 | 0.72 | GAA (0.49) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL8344463 | 0.72 | IDO1 (0.50) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL8344232 | 0.71 | METAP2 (0.51) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL24405876 | 0.68 | MAP3K5 (0.48) | CYP1A2CYP2C9CYP2C19MAP3K5RAB9A | |
| SCHEMBL10691319 | 0.68 | MAP3K5 (0.48) | MAP3K5RAB9ANPC1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| EP-1539700-A4 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LTD (AU) | 2006-06-28 | — | — | EP | disclosed |
| US-20060089380-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LTD. (AU) | 2006-04-27 | — | — | US | disclosed |
| CN-1681791-A | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LTD (AU) | 2005-10-12 | — | — | CN | disclosed |
| EP-1539700-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | Prana Biotechnology Ltd (AU) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | GAA 117/4885METAP2 1832/4885PLAU 2218/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | GAA 117/4885METAP2 1832/4885PLAU 2218/4885 |
| US-20060089380-A1 | 8-Hydroxy quinoline derivatives | PARK7, HTT, SNCA | GAA 125/4885METAP2 1648/4885PLAU 4436/4885 |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | GAA 117/4885METAP2 1832/4885PLAU 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.